| 7:45-8:30 a.m. |
Registration and Coffee
Crystal Ballroom Foyer |
| 8:30 a.m. |
Welcoming Remarks: Jane Salmon; Margaret Dowd and Susana Serrate-Sztein
Crystal Ballroom, Waterford/Lalique Suites |
| 8:40 a.m.-12:00 noon: |
Session I: Extrinsic and Intrinsic
Triggers of Autoimmunity
Crystal Ballroom, Waterford/Lalique Suites
|
|
Chair: David Pisetsky |
- David Pisetsky - The role of bacterial DNA in triggering anti-DNA
production in SLE
- Judith James -The role of EBV infection in the pathogenesis of
SLE
- Michael Lockshin - Speculations about the role of sex in SLE
- Valerie Fadok - The interaction of apoptotic cells with the immune
system
- Westley Reeves - The pristane model of SLE
|
| 12:00 noon-1:30 p.m. |
Lunch and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites
|
| 1:30-5:30 p.m. |
Session II: Predisposing Factors:
Genetics of SLE in Humans
Crystal Ballroom, Waterford/Lalique Suites
|
| Chair: Brian Kotzin |
- Brian Kotzin - Identification of genes that promote murine lupus
- Edward Wakeland - Identification of genes that suppress murine
lupus
- Mark Walport - SLE: A disease of disordered waste disposal
- Timothy Behrens - Genetic fine mapping in human SLE
- Lindsey Criswell - ACE polymorphisms in human SLE: importance of
genetic heterogeneity
- John Harley - Clinical variation holds genetic secrets of lupus
- Betty Tsao - Follow-up linkage studies in SLE
|
| 5:30 p.m.-7:30 p.m. |
Dinner and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites
|
| 7:30-9:30 p.m. |
Evening Workshops |
Basic Mechanisms I
Embassy Room |
| Chair: Gary Gilkeson and Joan
Merrill |
- Bahram Namjou - Stratification of pedigrees multiplex for arthritis
and systemic lupus erythematosus (SLE) detects an SLE susceptibility
gene at 5p15.3
- Silvia Bolland - Genetic modifiers of SLE in FcgammaRIIB-deficient
mice
- Susan Boackle - CR2, a candidate gene in the SLE1c lupus susceptibility
locus, encodes a dysfunctional protein in the NZM2410 mouse
- Elahna Paul - C4 deficiency attenuates the central regulation of
autoreactive B cells
- Yu Yang - A quantitative genetic trait for human lupus: low and
high gene dosages of complement C4 in SLE patients
- Guillermina Girardi - Complement activation mediates antiphopholipid
antibody (apl-ab)- induced pregnancy loss
- Hong Zhou - Induction of monocyte tissue factor expression and
activity by IgG from patients with the antiphospholipid syndrome
and inhibition by Dilazep, an adenosine uptake inhibitor
|
Basic Mechanisms II
Severn Suite |
| Chair: Joseph Craft and George
Tsokos |
- Florin Niculescu - Increased phosphatidylinositol-3 kinase (PI
3-kinase) and JNK1 activity is a feature of the pathogenic T cells
in a murine model of lupus
- Wendy Davidson - Evidence for Fas-dependent and Fas-independent
caspase-independent oncotic cell death pathways in T cells that are
triggered by TCR ligation
- Jun-Qi Yang- Functional insufficiency of NKT cells in lupus: studies
in CD1d-knockout NZB/NZW F1 mice
- Douglas Lienesch -Renal, splenic and circulatory TGF-beta levels
in mouse models of SLE
- Dama Laxminarayana - Mutations in protein kinase A (PKA) RI-alpha
gene transcripts and upregulation of mRNA editing gene expression
in SLE T lymphocytes.
- Violeta Rus - Gene expression analysis of cytokine and chemokine-related
genes in PBMC from lupus patients in disease flare and remission
- Nilamadhab Mishra - Histone deacetylase inhibitors are the candidates
for the treatment of Systemic Lupus Erythematosus
|
Basic Mechanisms III
Judiciary Suite |
| Chair: Mary Crow and Bruce Richardson. |
- Randy Cron - Identification of a novel GATA-regulated CD154 transcriptional
enhancer
- Mariana Kaplan - Multiple death-receptor pathways mediate APC cytotoxicity
induced by autoreactive lupus T cells
- Virginia Pascual - IFN-a: a novel therapeutic target in SLE
- Krishnan Sundar - Induction of antibodies to dsDNA and Sm in mice
immunized with EBNA-1 expressing plasmids
- Andrew Gross - High numbers of Epstein Barr Virus infected B lymphocytes
in the peripheral blood of patients with Systemic Lupus Erythematosus
- Allison Reiss - Serum from SLE patients compromises cholesterol
homeostasis in cultured human aortic endothelial cells (HAEC) by
decreasing cholesterol 27-hydroxylase expression
- Vivian Ng - Antibodies to domain II/III of apolipoprotein A1: correlation
to atherosclerotic factors in a lupus cohort
|
Epidemiology/Genetics/Clinical
Features
Susquehanna Suite |
| Chair: Rosalind Ramsey-Goldman
and Matthew Liang |
- Glinda Cooper - Occupational exposures and risk of Systemic Lupus
Erythematosus
- Victoria Werth - Strong association of a promoter polymorphism
of tumor necrosis factor- alpha (TNF-alpha) with a photosensitive
form of cutaneous lupus erythematosis
- Christine Parks - Systemic Lupus Erythematosus and genetic polymorphisms
in IL-1alpha, IL-1beta and IL-1 receptor antagonist: a population-based
case-control study
- Brad Rovin - A novel interleukin-8 (IL-8) polymorphism is associated
with severe SLE nephritis
- Sarah Thielman - Predominance of continued activity with advancing
chronicity in serial renal biopsies from patients with lupus nephritis
- Joan Merrill - Registry for the Antiphospoholipid Syndrome: association
of antiphospholipid antibodies with post-menopausal arterial events
- Sasha Bernatsky - A meta-analysis of clinical cohort studies of
malignancy in lupus
|
Treatment: Murine and Human
Studies
Cabinet Suite |
| Chair: David Horowitz and Dafna
Gladman |
- S.G. Zheng - Suppression of a lupus-like syndrome in mice with
regulatory T cells generated ex-vivo with Transforming Growth Factor-beta
- T. Zhou - An agonistic anti-human DR5 antibody as a potential therapeutic
agent in SLE
- Lena Schiffer - Remission of SLE nephritis induced by short-term
combination costimulatory blockade in NZB/W F1 mice is associated
with downregulation of expression of the chemokine BLC
- Juergen Foell - Immune intervention in the pathogenesis of SLE
by means of the CD137 (4-1BB) signaling pathway
- Amrie Grammer - Analysis of peripheral B cells following treatment
of active SLE patients with humanized anti-CD154 MAB (5C8,BG9588).
- Gregg Silverman - Development of B-cell superantigen therapy for
SLE
- D. Alarcon-Segovia - SLE trial shows fewer renal flares in LJP
394-treated patients with high-affinity antibodies to LJP 394
|
Friday, January 11, 2002 |
| 8:30 a.m. - 12:00 noon |
Session III: Immunoregulatory
Mechanisms
Crystal Ballroom, Waterford/Lalique Suites
|
| Chair: Katherine Siminovitch |
- Bevra Hahn - Immunoregulatory abnormalities in SLE
- Katherine Siminovitch - Roles of SH2 domain containing tyrosine
phosphatases in modulating lymphocyte activation
- Joseph Craft - Mechanisms of loss of T cell tolerance in SLE
- John O'Shea - Cytokine signaling and immunodeficiency
- Jane Gross - Role of BLyS and its receptors TAC1 and BCMA in B
cell development and regulation of autoimmune disease
- Peter Lipsky - B cells in SLE
|
| 12:00 noon - 2:00 p.m. |
Lunch and Poster Sessions
Crystal Ballroom, Haverford/Baccarat Suites
|
| 2:00 p.m. - 5:30 p.m. |
Session IV: Mediators of Tissue
Injury
Crystal Ballroom, Waterford/Lalique Suites |
| Chair: Jane Salmon |
- Jane Salmon - Complement activation as a mediator of anti-phospholipid
antibody-induced injury
- Jose-Carlos Gutierrez-Ramos - Genomic approaches for identifying
mediators of tissue injury
- Betty Diamond - A model for CNS injury in SLE
- Mark Ginsberg - Alpha 4 integrins and leukocyte trafficking
- Charles Esmon - Thrombosis as a target of inflammatory-mediated
injury
- Daniel Kastner - Mendelian disorders of inflammation
|
| 5:30 p.m.-7:30 p.m. |
Dinner and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites |
| 7:30 p.m. - 9:30 p.m. |
Evening Plenary Session:
Drug Trials and Tribulations
Crystal Ballroom, Waterford/Lalique Suites
|
| Saturday, January 12,
2002 |
| 8:30 a.m. - 12:00 noon |
Session V: Novel Therapies
Crystal Ballroom, Waterford/Lalique Suites |
| Chair: David Wofsy |
- James Balow - Cytotoxic therapy for lupus nephritis
- David Daikh - Targeting active immune responses in SLE by inhibition
of T cell costimulation
- Robert Eisenberg - Targeting B cells in SLE
- Richard Quigg - Treatment of SLE by inhibition of complement activation
- Michelle Petri - High-dose cyclophosphamide for SLE
- Ann Traynor - Immune diversity post-transplant: a mechanism for
achieving organ repair
|
12:00 noon
|
Adjourn |
Print Friendly Page
